Use of the tumor necrosis factor-blockers for Crohn's disease

doi:10.3748/wjg.v18.i35.4823

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7183)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-38) series.

Item

Count

PDF

639

HTML

6021

Figures (1-2)

265

Tables (1-38)

258

Sum=7183

Sep 21, 2012 (publication date) through Dec 1, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines For Clinical Practice

World J Gastroenterol. Sep 21, 2012; 18(35): 4823-4854
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823

Table 28 Associations of mucosal healing in Crohn's disease

Fewer symptoms
No previous surgery
Previous surgery
Less inflammation at 5 yr requiring steroid use
Less use of steroids
Steroid-free remission and no flare at years 3 and 4	Yes (TG, 44%)
Steroid-free remission, no flare and no TNFB at years 3 and 4	Yes (TG, 44%)
No new or persistently active fistulas	No

How do these associations with mucosal healing (MH) in CD compare with UC? About 90% of patients remain asymptomatic after achieving MH on once-a-day 5-aminosalicylic acid (Mezavant^®), and after MH, 40% of UC patients remain asymptomatic (TG, 22%). TG: Therapeutic gain; CD: Crohn's disease; UC: Ulcerative colitis; TNFB: Tumor necrosis factor-α blockers (response in active treatment group minus response in placebo group; differences statistically significant).

Citation: Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854
URL: https://www.wjgnet.com/1007-9327/full/v18/i35/4823.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i35.4823